Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce substantial weight loss (up to 20%) by acting on CNS neural circuits, specifically the dorsal vagal complex.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often resulting in 10-20% body weight reduction. They work by acting on brain circuits that control appetite. You must take them chronically, as stopping leads to weight regain. Side effects like nausea are common but manageable.
StrongSupportsVERY_HIGH confidence
Higher doses of semaglutide (sold as Wegovy) resulted in >10% placebo-corrected weight loss... a recent report has shown that an ablation of neurons in the dorsal vagal complex (DVC)... markedly attenuate the anorectic effect of semaglutide and exendin-4.
Why this rating
Supported by multiple clinical trials and mechanistic studies cited.
Source
On the causes of obesity and its treatment: The end of the beginning
Jeffrey M. Friedman · Cell Metabolism · 2025
DOI 10.1016/j.cmet.2025.01.026
narrative_reviewCited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a biologic disorder caused by alterations in CNS pathways controlling energy balance, not a lifestyle failure remediable by willpower alone.Strong
- Leptin therapy is effective for weight loss only in patients with leptin deficiency (low circulating levels), not in those with leptin resistance (high levels).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →